<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62092">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01931436</url>
  </required_header>
  <id_info>
    <org_study_id>QE-2458-2</org_study_id>
    <nct_id>NCT01931436</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of Qing'E Pill</brief_title>
  <official_title>A Single-site, Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics of the Main Components of Qing'E Pill (a Chinese Medicine Formula) Into the Blood in Chinese Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuxi People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the pharmacokinetics of single and multiple doses of Qing'E
      pills in Chinese menopause volunteers. The main components of Qing'E pill into the blood
      such as psoralen and Isopsoralen will be detected.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of the main components of Qing'E pill (Maximum plasma concentration (Cmax), Area under the plasma concentration curve (AUClast and AUC))</measure>
    <time_frame>Up to 48 hours postdose for each period</time_frame>
    <safety_issue>No</safety_issue>
    <description>To detect the main components of Qing'E pill into the blood such as psoralen and Isopsoralen.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Qing'E pill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered twice a day, and each 9 g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qing'E pill</intervention_name>
    <description>Qing'E pill is composed of eucommia, psoralen, walnuts and garlic.</description>
    <arm_group_label>Qing'E pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women age between 40 to 60 Years, Suffering from irregular menstrual cycle or
             amenorrhea of 3-11 months.

          2. Moderate to severe hot flashes (associated with sweating)≥5 times /24 hours.

          3. The score of Kupperman index is not less than 15.

          4. Patients unused estrogen tablets or progesterone injection in 6 months.

          5. Patients must discontinue other therapies in the treatment of menopausal syndrome for
             more than 3 months.

          6. Get subjects informed consent process should comply with GCP requirements.

        Exclusion Criteria:

          1. There is no clinical significance abnormal in physical and laboratory examination.

          2. Bilateral oophorectomy, endometrial lesions, uterine polyps, abnormal vaginal
             bleeding, severe breast hyperplasia, with family history of breast cancer.

          3. Patients with hypertension, primary hypotension and chronic anemia (Hb ≤ 90 g/L).

          4. Patients with hyperthyroidism, coronary atheroma, diabetes, obesity (body mass index
             of more than 30 kg/m2), migraine, malignant tumors, thromboembolic disease,
             gastrointestinal diseases affect absorption or autoimmune diseases.

          5. Patients with diseases of the cardiovascular, cerebrovascular, liver, kidney and
             hematopoietic system, or mentally ill.

          6. People with allergies.

          7. People taking other drugs within 14 days before the trail.

          8. Patients are participating in other clinical trials within 3 months.

          9. Pregnant Women.

         10. Alcoholics or smokers (past or smoking).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zheng Qingshan, MD</last_name>
    <phone>+86-021-51322556</phone>
    <email>zheng.zqs@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>210038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Jie, MD</last_name>
      <phone>+86-0510-85350351</phone>
      <email>yangjie@wuxiph.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 26, 2013</lastchanged_date>
  <firstreceived_date>August 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menopause, pharmacokinetic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
